

Betty Diamond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3951792/publications.pdf>

Version: 2024-02-01

156
papers

13,242
citations

44069

48
h-index

24258

110
g-index

161
all docs

161
docs citations

161
times ranked

13943
citing authors

#	ARTICLE	IF	CITATIONS
1	The gut microbiota influences blood-brain barrier permeability in mice. <i>Science Translational Medicine</i> , 2014, 6, 263ra158.	12.4	1,589
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
3	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2005, 353, 2550-2558.	27.0	962
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
5	A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. <i>Nature Medicine</i> , 2001, 7, 1189-1193.	30.7	721
6	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	14.5	501
7	Cognition and Immunity. <i>Immunity</i> , 2004, 21, 179-188.	14.3	386
8	Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19854-19859.	7.1	365
9	Immunity and behavior: Antibodies alter emotion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 678-683.	7.1	264
10	Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. <i>Journal of Clinical Investigation</i> , 2015, 125, 2194-2202.	8.2	232
11	Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. <i>Nature Immunology</i> , 2014, 15, 98-108.	14.5	231
12	Losing your nerves? Maybe it's the antibodies. <i>Nature Reviews Immunology</i> , 2009, 9, 449-456.	22.7	220
13	Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2010, 62, 201-210.	6.7	198
14	Similarities and differences between selective and nonselective BAFF blockade in murine SLE. <i>Journal of Clinical Investigation</i> , 2006, 116, 724-734.	8.2	196
15	Immunization with a Peptide Surrogate for Double-stranded DNA (dsDNA) Induces Autoantibody Production and Renal Immunoglobulin Deposition. <i>Journal of Experimental Medicine</i> , 1998, 188, 29-38.	8.5	184
16	Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18569-18574.	7.1	184
17	HMGB1 Mediates Cognitive Impairment in Sepsis Survivors. <i>Molecular Medicine</i> , 2012, 18, 930-937.	4.4	172
18	PD-1hiCXCR5+ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019, 4, .	5.0	171

#	ARTICLE	IF	CITATIONS
19	Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis. PLoS ONE, 2008, 3, e3347.	2.5	156
20	Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nature Medicine, 2009, 15, 91-96.	30.7	150
21	C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3160-7.	7.1	149
22	The intersection of COVID-19 and autoimmunity. Journal of Clinical Investigation, 2021, 131, .	8.2	138
23	C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood, 2016, 128, 2218-2228.	1.4	130
24	Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2004, 173, 3524-3534.	0.8	128
25	Tolerogenic function of Blimp-1 in dendritic cells. Journal of Experimental Medicine, 2011, 208, 2193-2199.	8.5	122
26	Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. Journal of Experimental Medicine, 2018, 215, 2554-2566.	8.5	117
27	Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis and Rheumatology, 2021, 73, 121-131.	5.6	117
28	Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 427.	4.8	102
29	Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature Communications, 2021, 12, 3391.	12.8	93
30	Increased cathepsin S in Prdm1 ^{hi} dendritic cells alters the TFH cell repertoire and contributes to lupus. Nature Immunology, 2017, 18, 1016-1024.	14.5	86
31	Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. Journal of Autoimmunity, 2009, 33, 270-274.	6.5	82
32	Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. Annals of the Rheumatic Diseases, 2021, 80, 203-208.	0.9	82
33	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open, 2019, 9, e025687.	1.9	81
34	Blood pressure regulation by CD4 ⁺ lymphocytes expressing choline acetyltransferase. Nature Biotechnology, 2016, 34, 1066-1071.	17.5	74
35	Randomized, Double-blind, Placebo-controlled Trial of the Effect of Vitamin D ₃ on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 1848-1857.	5.6	73
36	Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-d-Aspartate Receptor. EBioMedicine, 2015, 2, 755-764.	6.1	71

#	ARTICLE	IF	CITATIONS
37	Follicular Helper T Cells in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1793.	4.8	68
38	Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. <i>Journal of Clinical Investigation</i> , 2013, 123, 823-33.	8.2	68
39	Light Chain Usage in Anti-“double-stranded DNA B Cell Subsets: Role in Cell Fate Determination. <i>Journal of Experimental Medicine</i> , 1997, 185, 1317-1326.	8.5	66
40	Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 55, 434-441.	6.7	66
41	Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. <i>European Journal of Immunology</i> , 1999, 29, 1901-1911.	2.9	65
42	Checkpoints for Autoreactive B Cells in the Peripheral Blood of Lupus Patients Assessed by Flow Cytometry. <i>Arthritis and Rheumatology</i> , 2016, 68, 2210-2220.	5.6	65
43	HMGB1-“C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 23254-23263.	7.1	64
44	The generation of human monocyte/macrophage cell lines. <i>Nature</i> , 1983, 306, 597-599.	27.8	63
45	Integrated urine proteomics and renal single-cell genomics identify an IFN-“ response gradient in lupus nephritis. <i>JCI Insight</i> , 2020, 5, .	5.0	57
46	It takes guts to grow a brain. <i>BioEssays</i> , 2011, 33, 588-591.	2.5	56
47	C1q-Mediated Repression of Human Monocytes Is Regulated by Leukocyte-Associated Ig-Like Receptor 1 (LAIR-1). <i>Molecular Medicine</i> , 2014, 20, 559-568.	4.4	56
48	Fundamental role of C1q in autoimmunity and inflammation. <i>Immunologic Research</i> , 2015, 63, 101-106.	2.9	55
49	Investigational treatment of rheumatoid arthritis with a vibrotactile device applied to the external ear. <i>Bioelectronic Medicine</i> , 2019, 5, 4.	2.3	55
50	Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. <i>JCI Insight</i> , 2019, 4, .	5.0	52
51	High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation. <i>Frontiers in Immunology</i> , 2018, 9, 705.	4.8	51
52	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.9	51
53	A model for lupus brain disease. <i>Immunological Reviews</i> , 2012, 248, 56-67.	6.0	49
54	Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. <i>Nature Reviews Nephrology</i> , 2020, 16, 238-250.	9.6	48

#	ARTICLE	IF	CITATIONS
55	Antibodies as Mediators of Brain Pathology. <i>Trends in Immunology</i> , 2015, 36, 709-724.	6.8	47
56	HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors. <i>Molecular Medicine</i> , 2015, 21, 951-958.	4.4	45
57	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. <i>Arthritis and Rheumatology</i> , 2018, 70, 277-286.	5.6	45
58	Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression. <i>Scientific Reports</i> , 2017, 7, 270.	3.3	43
59	Female mouse fetal loss mediated by maternal autoantibody. <i>Journal of Experimental Medicine</i> , 2012, 209, 1083-1089.	8.5	42
60	The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. <i>Frontiers in Immunology</i> , 2017, 8, 1101.	4.8	42
61	Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials. <i>Arthritis and Rheumatology</i> , 2019, 71, 1413-1425.	5.6	41
62	T Cell Studies in a Peptide-Induced Model of Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2001, 166, 1667-1674.	0.8	40
63	Modulation of tolerogenic dendritic cells and autoimmunity. <i>Seminars in Cell and Developmental Biology</i> , 2015, 41, 49-58.	5.0	40
64	Differences in Regional Brain Activation Patterns Assessed by Functional Magnetic Resonance Imaging in Patients with Systemic Lupus Erythematosus Stratified by Disease Duration. <i>Molecular Medicine</i> , 2011, 17, 1349-1356.	4.4	39
65	Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. <i>European Journal of Immunology</i> , 1999, 29, 3168-3178.	2.9	38
66	Urine Proteomics and Renal <i>Single-Cell</i> Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	5.6	38
67	DNA-Containing Immunocomplexes Promote Inflammasome Assembly and Release of Pyrogenic Cytokines by CD14 ⁺ CD16 ⁺ CD64 ^{high} CD32 ^{low} Inflammatory Monocytes from Malaria Patients. <i>MBio</i> , 2015, 6, e01605-15.	4.1	37
68	Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. <i>Lupus Science and Medicine</i> , 2016, 3, e000159.	2.7	37
69	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
70	Pathogenic Anti-DNA Antibodies in SLE: Idiotypic Families and Genetic Origins. <i>International Reviews of Immunology</i> , 1990, 5, 295-313.	3.3	36
71	Loss of an IgG plasma cell checkpoint in patients with lupus. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1586-1597.	2.9	36
72	Lupus autoantibodies act as positive allosteric modulators at GluN2A-containing NMDA receptors and impair spatial memory. <i>Nature Communications</i> , 2020, 11, 1403.	12.8	36

#	ARTICLE	IF	CITATIONS
73	Autoimmune Disease-associated Haplotypes of <i>BLK</i> Exhibit Lowered Thresholds for B Cell Activation and Expansion of Ig Class-switched B Cells. <i>Arthritis and Rheumatology</i> , 2015, 67, 2866-2876.	5.6	35
74	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
75	HMGB1 in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 1057.	4.8	35
76	Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2015, 2, e000074-e000074.	2.7	34
77	Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts. <i>Journal of Experimental Medicine</i> , 2008, 205, 2437-2448.	8.5	33
78	DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 2824.	4.8	32
79	Targeting DEC-205 ⁺ DCIR2 ⁺ dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis. <i>Molecular Medicine</i> , 2018, 24, 17.	4.4	32
80	HIF-1 α is a negative regulator of interferon regulatory factors: Implications for interferon production by hypoxic monocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	31
81	Antibodies and the Brain: Lessons from Lupus. <i>Journal of Immunology</i> , 2010, 185, 2637-2640.	0.8	29
82	Structural modification of DNA—a therapeutic option in SLE?. <i>Nature Reviews Rheumatology</i> , 2011, 7, 733-738.	8.0	28
83	Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. <i>American Journal of Neuroradiology</i> , 2019, 40, 470-477.	2.4	28
84	Mapping the immunological homunculus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3461-3462.	7.1	27
85	Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	27
86	Enhanced Selection of High Affinity DNA-Reactive B Cells Following Cyclophosphamide Treatment in Mice. <i>PLoS ONE</i> , 2010, 5, e8418.	2.5	26
87	Hormonal milieu at time of B cell activation controls duration of autoantibody response. <i>Journal of Autoimmunity</i> , 2014, 53, 46-54.	6.5	26
88	Maternal antibodies and developing blood-brain barrier. <i>Immunologic Research</i> , 2015, 63, 18-25.	2.9	26
89	DNA-reactive B cells in lupus. <i>Current Opinion in Immunology</i> , 2016, 43, 1-7.	5.5	25
90	Patterns of ANA ⁺ B cells for SLE patient stratification. <i>JCI Insight</i> , 2019, 4, .	5.0	25

#	ARTICLE	IF	CITATIONS
91	Regional Brain Metabolism in a Murine Systemic Lupus Erythematosus Model. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1315-1320.	4.3	23
92	HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation. <i>Blood</i> , 2022, 139, 3181-3193.	1.4	23
93	Expression of Blimp-1 in Dendritic Cells Modulates the Innate Inflammatory Response in Dextran Sodium Sulfate-Induced Colitis. <i>Molecular Medicine</i> , 2014, 20, 707-719.	4.4	22
94	Commentary: Crossing the Atlantic: The Euro Lupus Nephritis Regimen in North America. <i>Arthritis and Rheumatology</i> , 2015, 67, 1144-1146.	5.6	22
95	Constitutive Vagus Nerve Activation Modulates Immune Suppression in Sepsis Survivors. <i>Frontiers in Immunology</i> , 2018, 9, 2032.	4.8	22
96	The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	21
97	Identification of DNA-reactive B cells in patients with systemic lupus erythematosus. <i>Journal of Immunological Methods</i> , 2008, 338, 79-84.	1.4	19
98	<scp>SLE</scp>-associated risk factors affect <scp>DC</scp> function. <i>Immunological Reviews</i> , 2016, 269, 100-117.	6.0	18
99	Dynamic Contrast-Enhanced MRI Reveals Unique Blood-Brain Barrier Permeability Characteristics in the Hippocampus in the Normal Brain. <i>American Journal of Neuroradiology</i> , 2019, 40, 408-411.	2.4	18
100	Therapeutics to block autoantibody initiation and propagation in systemic lupus erythematosus and rheumatoid arthritis. <i>Science Translational Medicine</i> , 2015, 7, 280ps5.	12.4	17
101	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020, 72, 233-242.	3.4	17
102	The immune tolerance network and rheumatic disease: Immune tolerance comes to the clinic. <i>Arthritis and Rheumatism</i> , 2001, 44, 1730-1735.	6.7	16
103	Lineage-Specific Functionality of an Interferon Regulatory Factor 5 Lupus Risk Haplotype: Lack of B Cell Intrinsic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 996.	4.8	16
104	IgG+, CD5+ Human Chronic Lymphocytic Leukemia B Cells. Production of IgG Antibodies That Exhibit Diminished Autoreactivity and IgG Subclass Skewing. <i>Autoimmunity</i> , 1994, 19, 39-48.	2.6	15
105	Immunization Elicits Antigen-Specific Antibody Sequestration in Dorsal Root Ganglia Sensory Neurons. <i>Frontiers in Immunology</i> , 2018, 9, 638.	4.8	15
106	Characterization of two Human Anti-DNA Antibodies Bearing the Pathogenic Idiotype 8.12. <i>Autoimmunity</i> , 1993, 16, 13-21.	2.6	14
107	The Genotype and Phenotype (GaP) registry: a living biobank for the analysis of quantitative traits. <i>Immunologic Research</i> , 2015, 63, 107-112.	2.9	14
108	Maternal Antibody and ASD: Clinical Data and Animal Models. <i>Frontiers in Immunology</i> , 2019, 10, 1129.	4.8	14

#	ARTICLE	IF	CITATIONS
109	Buprenorphine Markedly Elevates a Panel of Surrogate Markers in a Murine Model of Sepsis. <i>Shock</i> , 2019, 52, 550-553.	2.1	14
110	The magnitude of germinal center reactions is restricted by a fixed number of preexisting niches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	13
111	Blood-Brain Barrier Deterioration and Hippocampal Gene Expression in Polymicrobial Sepsis: An Evaluation of Endothelial MyD88 and the Vagus Nerve. <i>PLoS ONE</i> , 2016, 11, e0144215.	2.5	13
112	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. <i>Molecular Medicine</i> , 2018, 24, 24.	4.4	12
113	In utero exposure to endogenous maternal polyclonal anti-Caspr2 antibody leads to behavioral abnormalities resembling autism spectrum disorder in male mice. <i>Scientific Reports</i> , 2020, 10, 14446.	3.3	12
114	The Preferential Expression of the Anti-DNA Associated 8.12 Idiotype in Lupus is not Genetically Controlled. <i>Autoimmunity</i> , 1994, 18, 1-6.	2.6	11
115	Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. <i>Lupus Science and Medicine</i> , 2019, 6, e000327.	2.7	11
116	In utero exposure to maternal anti-aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. <i>Science Translational Medicine</i> , 2022, 14, eabe9726.	12.4	11
117	Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000559.	2.7	10
118	Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. <i>Lupus Science and Medicine</i> , 2017, 4, e000229.	2.7	8
119	Follicular dendritic cell dysfunction contributes to impaired antigen-specific humoral responses in sepsis-surviving mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	8
120	A structural investigation of FISLE-412, a peptidomimetic compound derived from saquinavir that targets lupus autoantibodies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4725-4729.	2.2	6
121	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	1.9	6
122	FcγRIIB regulates autoantibody responses by limiting marginal zone B cell activation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	6
123	Epinephrine Production in Th17 Cells and Experimental Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021, 12, 616583.	4.8	5
124	Introducing the MAVEN Leadership Training Initiative to diversify the scientific workforce. <i>ELife</i> , 2021, 10, .	6.0	5
125	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	2.7	5
126	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5

#	ARTICLE	IF	CITATIONS
127	Lupus anti-DNA antibodies bearing the 8.12 idiotype appear to be somatically mutated. <i>Journal of Clinical Immunology</i> , 1992, 12, 11-16.	3.8	4
128	Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport. <i>Frontiers in Immunology</i> , 2018, 9, 1599.	4.8	4
129	Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches. <i>Current Rheumatology Reports</i> , 2021, 23, 25.	4.7	4
130	Genetic recombination in the $\lambda 2$ domain of the ϵ chain yields an Ed molecule with altered T cell activation. <i>European Journal of Immunology</i> , 1990, 20, 2571-2576.	2.9	3
131	Effect of vitamin D on serum markers of bone turnover in SLE in a randomised controlled trial. <i>Lupus Science and Medicine</i> , 2019, 6, e000352.	2.7	3
132	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1505-1513.	1.9	3
133	SARS-CoV-2 and interferon blockade. <i>Molecular Medicine</i> , 2020, 26, 103.	4.4	3
134	Using the Mouse to Model Human Diseases: Cognitive Impairment in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 1145-1149.	2.0	3
135	Immune-mediated brain pathology: from autoantibodies to microglia. <i>Discovery Medicine</i> , 2016, 22, 201-207.	0.5	3
136	IL-17 ⁺ producing follicular Th cells enhance plasma cell differentiation in lupus-prone mice. <i>JCI Insight</i> , 2022, 7, .	5.0	3
137	AI-19 ⁺ T peripheral helper cells are expanded in the circulation of active SLE patients and correlate with CD21 ^{low} B cells. , 2018, , .		2
138	204 ⁺ ...The immune cell landscape in kidneys of lupus nephritis patients. , 2019, , .		2
139	Introduction to immunology at Feinstein Institute for Medical Research (FIMR). <i>Immunologic Research</i> , 2015, 63, 1-2.	2.9	1
140	Reply:. <i>American Journal of Neuroradiology</i> , 2019, 40, E42-E43.	2.4	1
141	Contributions of Sex Chromosomes and Gonadal Hormones to the Male Bias in a Maternal Antibody-Induced Model of Autism Spectrum Disorder. <i>Frontiers in Neurology</i> , 2021, 12, 721108.	2.4	1
142	Mimicry between DNA, Carbohydrates, and Peptides: Implications in Systemic Lupus Erythematosus. , 0, , 127-141.		1
143	Letter from Incoming Editor in Chief of Molecular Medicine, Dr. Betty Diamond. <i>Molecular Medicine</i> , 2014, 20, 331-331.	4.4	0
144	TD-05 ⁺ ...Dynamic contrast enhanced MRI (DCE-MRI) demonstrates hippocampus permeability in SLE. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
145	CT-03â€¦Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis. , 2018, , .		0
146	178â€¦Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis. , 2019, , .		0
147	AB0167â€¦SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCASIAN PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY. , 2019, , .		0
148	205â€¦Single cell RNA expression in lupus nephritis comparing african-american and caucasian patients identifies differential expression of type I interferon pathway. , 2019, , .		0
149	<i>Reply:</i>. American Journal of Neuroradiology, 2019, 40, E67-E68.	2.4	0
150	Anti-DNA antibodies. , 2021, , 231-235.		0
151	The brain in SLE. , 2021, , 231-255.		0
152	Contribution of BAFF and DNAâ€¦containing Immune Complexes to the Generation of DNAâ€¦reactive B cells. FASEB Journal, 2008, 22, 668.17.	0.5	0
153	Inhibition of Human Erythropoiesis during Inflammation Is Mediated By High Mobility Group Box Protein 1 (HMGB1) through Decreased Commitment of Hematopoietic Stem Cells to the Erythroid Lineage and By Increased Apoptosis of Terminally Differentiating Erythroblasts. Blood, 2016, 128, 702-702.	1.4	0
154	B-Cell Mediated Humoral Responses Are Impaired in Sepsis Survivors. Blood, 2018, 132, 1123-1123.	1.4	0
155	Reduced expression of inflammation regulatory proteins, ETSâ€¦1 and TNIPâ€¦1, may cause lupus in humans. FASEB Journal, 2019, 33, 523.4.	0.5	0
156	1509â€¦Differences in chromatin architecture pre- and post-induction therapy in pediatric lupus patients. , 2021, , .		0